Brain metastases often occur as a result of advanced cancer, and despite medical innovations, are still associated with a ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Scientists from Institut Curie, the CNRS, and Inserm have just created a novel class of molecules capable of destroying ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer ...

Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic and primary breast cancers, ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

With your cancer care team, you will develop a treatment plan that considers several factors, including potential side ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...